No Data
No Data
Kezar Life Sciences Appoints New Principal Accounting Officer
Jefferies Maintains Kezar Life Sciences(KZR.US) With Buy Rating, Cuts Target Price to $18
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Kezar Life Sciences Price Target Lowered to $7 From $9 at Wells Fargo
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences